---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-037214"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:12:30.707644+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology Q3 net loss narrows to $3.9M; cash of $14.1M supports 12-month runway

## Summary
- Cash totaled $14.1M as of Sep 30, 2022, up from $10.6M at Dec 31, 2021; proceeds from July IPO added.
- R&D expenses rose to $2.3M (Q3 2022) vs $1.1M (Q3 2021) due to THIO trial startup and clinical prep.
- Net loss improved to $3.9M (Q3 2022) from $5.2M (Q3 2021), primarily due to prior-year loss on convertible notes.
- Presented THIO-101 Phase 2 trial design at ESMO 2022; plans to report safety data in Q4 2022 and efficacy data in 2023.
- Added to Longevity Stock Index; preclinical data for THIO in hepatocellular carcinoma presented at Triple Meeting Symposium.

## SEC filing metadata
- accession: 0001564590-22-037214
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000156459022037214/0001564590-22-037214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000156459022037214/maia-8k_20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-037214
- JSON: https://secwatch.observer/filing/0001564590-22-037214.json
- Plain text: https://secwatch.observer/filing/0001564590-22-037214.txt

## Key facts
- Earnings Releases
  MAIA Biotechnology, Inc. reported third quarter ended September 30, 2022 results: net income Net loss was approximately $3.9 million.
  - Period: third quarter ended September 30, 2022
  - Net income: Net loss was approximately $3.9 million
  - Result: reported results
  source text: MAIA Biotechnology Reports Third Quarter 2022 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000156459022037214/0001564590-22-037214-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.